{
  "pmcid": "12433767",
  "sha256": "64e0964eef8edd4f4a1e4cedc0751b6fec4906ec5eeeacd3f386fb3f1e51ef8d",
  "timestamp_utc": "2025-11-09T23:38:00.927094+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 8.667130635524174,
    "reading_ease": 49.65334125475289,
    "word_count": 263
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Long-term Effectiveness of Fluoroscopy-Guided Foam Sclerotherapy for Varicose Veins: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This randomised controlled trial was conducted at the authors' center from August 1, 2011, to May 31, 2016."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were consecutive patients with varicose veins in the legs."
      },
      "Intervention": {
        "score": 1,
        "evidence": "The intervention involved fluoroscopy-guided foam sclerotherapy, with no comparator group mentioned."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the long-term effectiveness of fluoroscopy-guided foam sclerotherapy for varicose veins in the legs."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the recurrence of varicose veins, defined as their presence regardless of symptoms, assessed at the last follow-up in May 2022."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not specified."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding details were not provided."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 94 patients (58.3 ± 7.8 years; 43 men; 119 legs) were included in the final analysis."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "A total of 94 patients (58.3 ± 7.8 years; 43 men; 119 legs) were included in the final analysis."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The recurrence rate was 30.9% (29/94), with 26.6% (25/94) for the great saphenous vein and 4.3% (4/94) for the small saphenous vein (P < .001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Hyperpigmentation occurred in 11.8% (14/119) of legs. No stroke, deep vein thrombosis, or pulmonary embolism was reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}